These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37096763)

  • 41. Disease-Free Survival and Time to Complete Response After Definitive Chemoradiotherapy for Squamous-Cell Carcinoma of the Anus According to HIV Infection.
    Camandaroba MPG; Iseas S; Oliveira C; Taboada RG; Xerfan MP; Mauro CC; Silva VS; Barros M; de Jesus VHF; Felismino T; Aguiar S; Gobo ML; Mello CA; Riechelmann RP
    Clin Colorectal Cancer; 2020 Sep; 19(3):e129-e136. PubMed ID: 32389596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal.
    Wong CS; Tsao MS; Sharma V; Chapman WB; Pintilie M; Cummings BJ
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):309-14. PubMed ID: 10487550
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
    Roohipour R; Patil S; Goodman KA; Minsky BD; Wong WD; Guillem JG; Paty PB; Weiser MR; Neuman HB; Shia J; Schrag D; Temple LK
    Dis Colon Rectum; 2008 Feb; 51(2):147-53. PubMed ID: 18180997
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
    Thind G; Johal B; Follwell M; Kennecke HF
    Radiat Oncol; 2014 May; 9():124. PubMed ID: 24885554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy.
    Wexler A; Berson AM; Goldstone SE; Waltzman R; Penzer J; Maisonet OG; McDermott B; Rescigno J
    Dis Colon Rectum; 2008 Jan; 51(1):73-81. PubMed ID: 18066626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Population-Based Cohort Analysis of Chemoradiation Versus Radiation Alone for Definitive Treatment of Stage I Anal Cancer in Older Patients.
    Buckstein M; Arens Y; Wisnivesky J; Gaisa M; Goldstone S; Sigel K
    Dis Colon Rectum; 2018 Jul; 61(7):787-794. PubMed ID: 29771796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
    Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
    Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Salvage Abdominoperineal Resection for Squamous Cell Anal Cancer: A 30-Year Single-Institution Experience.
    Hagemans JAW; Blinde SE; Nuyttens JJ; Morshuis WG; Mureau MAM; Rothbarth J; Verhoef C; Burger JWA
    Ann Surg Oncol; 2018 Jul; 25(7):1970-1979. PubMed ID: 29691737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy.
    Hocquelet A; Auriac T; Perier C; Dromain C; Meyer M; Pinaquy JB; Denys A; Trillaud H; Denis De Senneville B; Vendrely V
    Eur Radiol; 2018 Jul; 28(7):2801-2811. PubMed ID: 29404766
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Squamous cell carcinoma of the anal margin: the university of Florida experience.
    Balamucki CJ; Zlotecki RA; Rout WR; Newlin HE; Morris CG; Kirwan JM; George TJ; Mendenhall WM
    Am J Clin Oncol; 2011 Aug; 34(4):406-10. PubMed ID: 20881476
    [TBL] [Abstract][Full Text] [Related]  

  • 51. VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
    Feliu J; Garcia-Carbonero R; Capdevila J; Guasch I; Alonso-Orduna V; Lopez C; Garcia-Alfonso P; Castanon C; Sevilla I; Cerezo L; Conill C; Quintana-Angel B; Sanchez ME; Ghanem I; Martin-Richard M; Lopez-Gomez M; Leon A; Caro M; Fernandez T; Maurel J
    Cancer Med; 2020 Feb; 9(3):1008-1016. PubMed ID: 31851776
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
    El-Hadaad HA; Wahba HA; Roshdy S
    J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival following salvage abdominoperineal resection for persistent and recurrent squamous cell carcinoma of the anus: do these disease categories affect survival?
    Severino NP; Chadi SA; Rosen L; Coiro S; Choman E; Berho M; Wexner SD
    Colorectal Dis; 2016 Oct; 18(10):959-966. PubMed ID: 26850085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma.
    Allal AS; Waelchli L; Bründler MA
    Clin Cancer Res; 2003 Dec; 9(17):6489-96. PubMed ID: 14695153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
    Gunderson LL; Moughan J; Ajani JA; Pedersen JE; Winter KA; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):638-45. PubMed ID: 24035327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma.
    Soares PC; Abdelhay ES; Thuler LCS; Soares BM; Demachki S; Ferro GVR; Assumpção PP; Lamarão LM; Ribeiro Pinto LF; Burbano RMR
    BMC Gastroenterol; 2018 Feb; 18(1):30. PubMed ID: 29466950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer.
    Owczarczyk K; Prezzi D; Cascino M; Kozarski R; Gaya A; Siddique M; Cook GJ; Glynne-Jones R; Goh V
    Radiother Oncol; 2019 May; 134():119-126. PubMed ID: 31005205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. External validation of a composite bio-humoral index in anal cancer patients undergoing concurrent chemoradiation.
    Franco P; Porreca A; Mantello G; Valvo F; Gasparini L; Slim N; Manfrida S; De Felice F; Gerardi MA; Vagge S; Krengli M; Palazzari E; Osti MF; Gonnelli A; Catalano G; Pittoni P; Ivaldi GB; Lupattelli M; Rosetto ME; Niespolo RM; Guido A; Durante O; Macchia G; Munoz F; El Khouzai B; Lucido MR; Arcadipane F; Casadei Gardini A; Maria D'Angelillo R; Gambacorta MA; Genovesi D; Di Nicola M; Caravatta L
    Radiother Oncol; 2022 Dec; 177():9-15. PubMed ID: 36273737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temporal increase in the incidence of anal squamous cell carcinoma in Kentucky and factors associated with adverse outcomes.
    O'brien SJ; Gaskins JT; Ellis CT; Martin BA; Mcdowell J; Gondim DD; Galandiuk S
    Cancer Med; 2023 May; 12(10):11462-11474. PubMed ID: 36991580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.